Summit sheds light on PCSK9i to reduce LDL cholesterol

The drug lowers cholesterol by 60% when combined with statin

March 15, 2017 12:49 am | Updated 12:49 am IST

Pune: The recently concluded International Diabetes Summit at the city-based Chellaram Diabetes Institute (CDI) shed light on the use of PCSK9 inhibitors (PCSK9i) to lower cholesterol levels and reduce the risk of heart attacks.

The PCSK9i are a new class of injectable drugs that reportedly reduce ‘bad’ cholesterol levels by up to 60% when combined with a statin (another class of drugs prescribed to help lower cholesterol levels).

“Statins are said to reduce the risk of heart attack by 25% to 30%. These block the enzyme that control production of LDL cholesterol. However, they do not completely remove the risk of heart attacks, which makes research of new products necessary,” said Dr. Vinaya Simha, consultant, Endocrinology, and assistant professor, Department of Internal Medicine at the U.S.-based Mayo Clinic.

Low-density lipoprotein cholesterol, abbreviated as LDL-c, is considered the ‘bad’ variant of cholesterol as it contributes to plaque deposition, leading to the hardening and narrowing of arteries or ‘atherosclerosis’ (thickening of artery walls owing to accumulation of white blood cells).

Function of the drugs

The drugs inactivate a protein in the liver called proprotein convertase subtilisin/kexin type 9 (PCSK9). The protein de-activates the receptors on the liver cell surface that transport LDL into the liver for break down. Without these receptors, more ‘bad’ cholesterol remains and accumulates in the blood.

PCSK9 inhibitors may be used alone or in combination with statins to lower the ‘bad’ cholesterol levels in patients who cannot tolerate any statin drug.

Dr. A. G. Unnikrishnan, CEO and chief Endocrinologist at CDI, said, “Controlling cholesterol level with diet and exercise is important. PCSK9 inhibitors are not available in India as of now, [but] they seem to be a promising mode of reducing risk of heart attacks.”

PCSK9 inhibitors are currently under clinical trial in India.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.